T2 Biosystems Named a “Fierce 15” Medical Device and Diagnostic Company of 2012

T2 Biosystems Named a “Fierce 15” Medical Device and Diagnostic Company of 2012

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been named to the “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.  Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their promising technologies and market opportunities, top management teams and notable financial backing. T2 Biosystems was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.

“We will watch this company closely as it gears up for human clinical trials in 2013 for its T2Candida rapid diagnostic assay and a de novo regulatory submission later in that year. The test is a game-changer,” said Hollmer.

“We are honored to be selected as a member of the ‘Fierce 15’, an award that highlights T2 Biosystems’ potential to make a fundamental change in the diagnosis of diseases with our proprietary T2MR detector,” said John McDonough, CEO, T2 Biosystems. “Our dedicated scientists and engineers have created a technology that enables rapid, direct detection from any clinical sample, including blood, sputum and urine. Our initial assay panel, T2Candida, will aid in the reduction of the estimated 40% mortality rate associated with infection through its ability to identify species-specific directly from whole blood in about two hours, compared with current detection methods that take from two to five days.”

T2 Biosystems is developing the first-ever diagnostic system capable of direct detection in any clinical sample for accurate detection of molecular and immunological targets. T2 Biosystems has presented preclinical data on its assays currently in development: T2Candida will aid in the reduction of the mortality rate associated with infection through rapid, sensitive, and specific species detection; T2Hemostasis, which is capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument; and T2Endotoxin, a novel method to screen injectable drugs and medical devices for the presence of endotoxins that are produced by gram negative bacteria or fungi.

An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations and post-marketing. Sign up is free at .

FierceMarkets, a wholly owned subsidiary of Questex Media Group, is a leader in B2B emedia, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, and finance industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of publications reaches more than 1.3 million executives in more than 100 countries.

Current publications include: : ; : ; : ; : ; : ; :; :

T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company’s products detect molecular, hemostasis or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices. For more information, please visit .